FDA Bioresearch Monitoring (BIMO) and 21 CFR Part 58 GLP Device Guide
Guide to FDA Bioresearch Monitoring (BIMO) and 21 CFR Part 58 GLP for device sponsors, covering compliance manuals, NAI/VAI/OAI, and PMA pre-approval audits.
Why Bioresearch Monitoring and GLP Control Your Device Clearance Timeline
Medical device manufacturers spend millions of dollars and years of development generating nonclinical safety data and clinical trial evidence to support 510(k) clearances, De Novo classifications, and Premarket Approvals (PMAs). Yet one critical regulatory reality is frequently overlooked until late in the development cycle: the U.S. Food and Drug Administration (FDA) does not accept submission data on trust alone.
Through its Bioresearch Monitoring (BIMO) program, FDA actively inspects clinical trial sites, study sponsors, contract research organizations (CROs), Institutional Review Boards (IRBs), and nonclinical testing laboratories. If BIMO inspectors discover compromised data integrity, unapproved protocol deviations, inadequate sponsor oversight, or noncompliance with 21 CFR Part 58 Good Laboratory Practice (GLP) standards, the consequences can be catastrophic. FDA can reject study datasets, issue Form FDA 483 observation notices and Warning Letters, initiate clinical investigator disqualification proceedings, or refuse to approve a PMA application.
Furthermore, BIMO compliance is evolving rapidly. While the core GLP framework in 21 CFR Part 58 has remained largely unchanged since its codification, FDA has been working to modernize Part 58 to introduce a GLP Quality System and address multisite global studies. Simultaneously, FDA's Office of Bioresearch Monitoring Inspectorate (OBMI) has intensified foreign site inspections, targeting foreign GLP contract testing laboratories that supply biocompatibility and safety data for U.S. device submissions.
This guide provides device regulatory, clinical, and quality leaders with an authoritative analysis of the FDA BIMO program and 21 CFR Part 58 GLP rules: how BIMO is structured across specific Compliance Programs, how Part 58 governs device nonclinical testing, how inspections are classified (NAI, VAI, OAI), how investigator disqualification impacts submissions, why original PMAs face mandatory BIMO audit, and how to maintain inspection readiness across domestic and offshore testing partners.
What Is the FDA Bioresearch Monitoring (BIMO) Program?
Origins and Statutory Purpose
FDA established the Bioresearch Monitoring (BIMO) program in 1977 as a targeted, agency-wide comprehensive program of on-site inspections and data audits. BIMO was created in response to congressional investigations and agency audits during the mid-1970s that revealed alarming deficiencies in clinical and nonclinical research, including fabricated laboratory records, unreported animal deaths, compromised clinical protocol adherence, and inadequate sponsor oversight.
The BIMO program operates under two foundational mandates:
- Data Integrity and Quality: Verifying that clinical and nonclinical data submitted to FDA in support of research permits and marketing applications (such as IDEs, 510(k)s, De Novos, and PMAs) are accurate, complete, and reliable.
- Subject Protection: Ensuring that the rights, safety, and welfare of human research subjects participating in FDA-regulated clinical trials are fully protected, and that animal subjects in nonclinical safety studies are treated humanely in compliance with established protocols.
BIMO is not a single office; it is a cross-cutting compliance regime executed by FDA field investigators managed by the Office of Bioresearch Monitoring Inspectorate (OBMI) within the Office of Regulatory Affairs (ORA), working in close coordination with center-level compliance units, including the CDRH Division of Bioresearch Monitoring within the Center for Devices and Radiological Health.
The Four BIMO Compliance Programs Governing Medical Device Submissions
FDA operationalizes BIMO inspections through standardized instruction manuals known as Compliance Program Guidance Manuals (CPGMs). Each manual dictates how field investigators prepare for, conduct, and report inspections of specific entities in the research supply chain.
For medical device sponsors, four primary BIMO compliance programs apply:
| Compliance Program | Target Entity | Core Focus for Medical Device Submissions | Primary Regulations Audited | Current Issuance / Status |
|---|---|---|---|---|
| CP 7348.811 | Clinical Investigators & Sponsor-Investigators | Audits clinical trial sites conducting device Investigational Device Exemption (IDE) or postmarket studies. Verifies protocol adherence, IRB approval, informed consent, protocol deviations, and source data verification against case report forms (CRFs). | 21 CFR Part 812 (IDE) 21 CFR Part 50 (Informed Consent) 21 CFR Part 56 (IRB) |
Issued 07/22/2020 |
| CP 7348.810 | Sponsors and Contract Research Organizations (CROs) | Audits device manufacturers and their contracted CROs. Evaluates sponsor selection and monitoring of investigators, protocol control, trial monitoring reports, safety reporting (unanticipated adverse device effects), and data management. | 21 CFR Part 812 Subpart C & D 21 CFR Part 54 (Financial Disclosure) 21 CFR Part 11 (Electronic Records) |
Active CPGM Chapter 48 |
| CP 7348.809 | Institutional Review Boards (IRBs) | Audits institutional and independent IRBs reviewing device clinical trials. Evaluates initial and continuing study review, voting quorum, membership composition, risk determination (significant vs. non-significant risk device determinations), and record retention. | 21 CFR Part 56 (IRBs) 21 CFR Part 812.60 |
Issued 04/04/2025 |
| CP 7348.808 | Good Laboratory Practice (GLP) Nonclinical Laboratories | Audits domestic and foreign nonclinical testing facilities conducting safety, biocompatibility, and toxicology studies supporting device submissions. Audits facility equipment, Study Director oversight, Quality Assurance Unit (QAU) independence, and raw data integrity. | 21 CFR Part 58 (GLP) | Active CPGM Chapter 48 |
How BIMO Interacts with Device Submission Types
Understanding which compliance program applies to your submission depends on the study phase and test type:
- 510(k) Premarket Notifications: BIMO audits for 510(k) submissions primarily center on CP 7348.808 (GLP) for nonclinical safety and biocompatibility studies conducted under ISO 10993. If clinical data is submitted to establish substantial equivalence, CP 7348.811 and CP 7348.810 apply.
- PMA Applications: Original PMAs undergo mandatory pre-approval BIMO inspections. CDRH automatically assigns BIMO audits covering the pivotal clinical trial sites (CP 7348.811), the device sponsor/CRO headquarters (CP 7348.810), and key nonclinical GLP safety testing labs (CP 7348.808).
- FDA 522 Postmarket Surveillance Studies: Studies ordered under Section 522 of the FD&C Act are subject to BIMO audit under CP 7348.811 and CP 7348.810 to verify postmarket safety data validity.
21 CFR Part 58 GLP: Governing Nonclinical Safety and Biocompatibility Testing
While Good Clinical Practice (GCP) governs human clinical trials, nonclinical safety testing for medical devices is governed by 21 CFR Part 58 Good Laboratory Practice for Nonclinical Laboratory Studies.
Scope of Part 58 for Medical Devices
Part 58 applies to in vivo and in vitro nonclinical laboratory studies conducted to assess the safety of FDA-regulated products. For medical device manufacturers, Part 58 applies directly to:
- Biocompatibility Testing: ISO 10993 cytotoxicity, sensitization, irritation, systemic toxicity, genotoxicity, implantation, and hemocompatibility studies (see our ISO 10993 Biocompatibility Guide).
- Toxicology Studies: Extractables and leachables safety evaluations, carcinogenicity, and reproductive toxicity studies.
- Animal Safety and Performance Studies: In vivo animal models evaluating acute and chronic tissue response, vascular patency, device deployment safety, and mechanical integrity inside living tissue.
Crucial Distinction: Basic exploratory research, initial material screening, routine quality control testing of production lots, and physical bench testing (e.g., tensile testing or fatigue testing) are exempt from 21 CFR Part 58. However, any nonclinical study intended to prove safety in a regulatory submission must strictly comply with Part 58.
+-----------------------------------------------------------------------+
| MEDICAL DEVICE NONCLINICAL EVIDENTIARY LANDSCAPE |
+-----------------------------------------------------------------------+
|
+------------------------+------------------------+
| |
v v
+---------------------------+ +---------------------------+
| Physical Bench Testing | | Nonclinical Safety & |
| & QC Lot Release | | Biocompatibility Studies |
+---------------------------+ +---------------------------+
| - Tensile / Fatigue | | - ISO 10993 Biocompat. |
| - Electrical Safety | | - Toxicological Risk Eval |
| - Package Integrity | | - In Vivo Animal Safety |
+---------------------------+ +---------------------------+
| |
v v
+---------------------------+ +---------------------------+
| EXEMPT from 21 CFR Part 58| | Governed by 21 CFR Part 58|
| Subject to ISO 17025 / | | Audited under BIMO |
| Design Controls (820.30) | | Compliance Program 7348.808|
+---------------------------+ +---------------------------+
Core Structural Requirements of 21 CFR Part 58
To comply with 21 CFR Part 58, a testing facility must establish rigid operational roles, documentation standards, and quality oversight:
1. The Study Director (§ 58.33)
For every GLP study, the testing facility must designate a single individual as the Study Director. The Study Director serves as the single point of control for the study's execution, scientific interpretation, and final reporting. Responsibilities include approving the study protocol, ensuring technical personnel adhere to written SOPs, documenting protocol amendments or deviations, and signing the final study report certifying GLP compliance.
2. The Quality Assurance Unit (QAU) (§ 58.35)
Every GLP testing facility must maintain an independent Quality Assurance Unit (QAU). To preserve objectivity, QAU personnel cannot be involved in the direct conduct of the study they monitor. The QAU is responsible for:
- Maintaining a master schedule of all GLP studies at the facility.
- Reviewing study protocols for GLP compliance.
- Conducting periodic, independent inspections of study phases and facility operations.
- Submitting written status reports to management and the Study Director.
- Signing a formal statement included in the final report stating dates when inspections were made and findings reported to management.
3. Standard Operating Procedures (SOPs) (§ 58.81)
A GLP laboratory must maintain written SOPs approved by management for every operational process, including test article handling, reagent preparation, equipment calibration and maintenance, animal care, environmental controls, and data collection. Any deviation from an SOP must be authorized by the Study Director and documented in the raw data.
4. Raw Data and Archiving (§ 58.190 & § 58.195)
GLP defines "raw data" as any original worksheets, records, notes, automated data collector printouts, photographs, or microfiche generated during the study. All raw data, protocols, specimens, and final reports must be retained in a secure, fire-resistant archive managed by an assigned archivist. For medical device submissions, raw data must be retained for at least 2 years following marketing approval or for at least 5 years following submission to FDA.
How BIMO Inspections Classify Sites: NAI, VAI, and OAI
At the conclusion of a BIMO inspection (whether auditing a clinical investigator, sponsor, IRB, or GLP lab), the FDA investigator conducts an exit interview with management and issues Form FDA 483 if objectionable conditions were observed.
Following field review and center evaluation (CDRH/OBMI), FDA assigns the inspection a final official classification:
+----------------------------------------------+
| FDA BIMO INSPECTION CONDUCTED |
+----------------------------------------------+
|
v
+----------------------------------------------+
| FDA Field Investigator Issues Form FDA 483 |
| (if objectionable conditions seen) |
+----------------------------------------------+
|
v
+----------------------------------------------+
| CDRH / OBMI Final Classification |
+----------------------------------------------+
|
+-----------------------------+-----------------------------+
| | |
v v v
+--------------------+ +--------------------+ +--------------------+
| No Action Indicated| |Voluntary Action Ind| | Official Action Ind|
| (NAI) | | (VAI) | | (OAI) |
+--------------------+ +--------------------+ +--------------------+
| No objectionable | | Minor/objectionable| | Serious, systemic, |
| conditions found. | | conditions found, | | or data integrity |
| Data accepted | | but no regulatory | | violations. Data |
| without restriction| | action required. | | rejected/escalated |
+--------------------+ +--------------------+ +--------------------+
1. No Action Indicated (NAI)
- Meaning: No objectionable conditions or administrative deviations were observed during the inspection, or the noted conditions were trivial.
- Submission Impact: Data from the audited site or study is accepted without regulatory restriction.
2. Voluntary Action Indicated (VAI)
- Meaning: Objectionable conditions were identified (e.g., minor protocol deviations, incomplete training logs, minor SOP lapses), but the deviations do not compromise overall data integrity or subject safety. FDA does not take formal administrative or enforcement action.
- Submission Impact: The sponsor or site is expected to voluntarily implement corrective actions. Submission data is generally accepted, though FDA may request additional justification or data validation.
3. Official Action Indicated (OAI)
- Meaning: Severe noncompliance, systemic failure, or intentional data falsification was uncovered (e.g., failure to obtain informed consent, fabricated raw data, lack of Study Director oversight, total QAU breakdown, unapproved protocol modifications).
- Submission Impact: Regulatory action is initiated. FDA issues Warning Letters, Untitled Letters, or Form FDA 483 responses demanding immediate remediation. Crucially, FDA may reject data from the audited site or declare the entire study invalid for regulatory submission.
Clinical Investigator Disqualification and the Escalation Cascade
When a clinical investigator auditing under CP 7348.811 receives an OAI classification for repeated or deliberate noncompliance, FDA can initiate formal administrative proceedings to remove the investigator from the clinical research ecosystem.
The Disqualification Process (NOOH Cascade)
[OAI Finding] ---> [Form FDA 483 / Warning Letter]
|
v
[Notice of Opportunity for Hearing (NOOH) Issued (§ 812.119)]
|
+------------+------------+
| |
v v
[Investigator Consents / [Investigator Requests Hearing]
Waives Hearing] |
| v
| [Presiding Officer Review]
| |
+------------+------------+
|
v
[Final Order of Disqualification Published in FDA Database]
|
v
[Data Excluded from Pending / Future Device Submissions]
- Warning Letter & Response Failure: FDA issues a Warning Letter detailing repeated or deliberate violations of 21 CFR Part 812, Part 50, or Part 56.
- Notice of Opportunity for Hearing (NOOH): If responses are inadequate, the FDA Center Director issues a formal NOOH proposing that the investigator be disqualified.
- Hearing or Waiver: The investigator may request an administrative hearing before a Presiding Officer or consent to disqualification.
- Disqualification Order: Upon final decision, FDA enters an Order of Disqualification. The investigator's name is added to the publicly available FDA Clinical Investigators Disqualification Proceedings Database.
Consequences for Device Sponsors
A disqualified investigator is legally ineligible to receive investigational medical devices or conduct any FDA-regulated study.
For a device sponsor with a pending 510(k) or PMA, investigator disqualification triggers severe collateral consequences:
- Data Exclusion: FDA routinely excludes all clinical data generated by the disqualified investigator from consideration in pending marketing applications.
- Sample-Size Deficits: If the excluded investigator enrolled a substantial portion of patients in a pivotal IDE study, the remaining dataset may lose statistical power, forcing the sponsor to recruit additional patients or restart clinical trials.
- Data Audit Requirements: FDA may require an independent third-party audit of all remaining clinical sites in the IDE trial to verify that systemic noncompliance was not widespread.
Why Original PMAs Must Clear a CDRH BiMo Inspection
For 510(k) clearances, BIMO inspections are typically conducted on a risk-based sample basis or triggered by specific data anomalies. However, for original Premarket Approval (PMA) applications, BIMO inspections are a mandatory pre-approval gate.
The PMA BiMo Pre-Approval Workflow
Under CDRH internal operating procedure, once an original PMA application is accepted for filing, the CDRH Division of Bioresearch Monitoring automatically receives notification. The division coordinates with OBMI to assign field investigators to inspect:
- Pivotal Clinical Trial Sites: Selection is based on high patient enrollment, high protocol deviation rates, high adverse event reporting rates, or sites managed by first-time principal investigators.
- Sponsor / CRO Headquarters: Evaluating overall study monitoring, electronic data capture (EDC) auditing, clinical supply chain tracking, and safety reporting under 21 CFR Part 812.
- Key Nonclinical GLP Laboratories: Inspecting the primary laboratories that generated safety and biocompatibility data.
+-------------------------------------------------------------------------+
| ORIGINAL PMA APPLICATION SUBMITTED TO CDRH |
+-------------------------------------------------------------------------+
|
v
+-------------------------------------------------------------------------+
| CDRH Filing Acceptance & BiMo Division Notification |
+-------------------------------------------------------------------------+
|
v
+-------------------------------------------------------------------------+
| OBMI Field Assignment of Pre-Approval BIMO Audits |
+-------------------------------------------------------------------------+
| | |
v v v
+-------------------+ +-------------------+ +-------------------+
| Clinical Site | | Sponsor / CRO HQ | | Foreign GLP Lab |
| Audits (CP 7348.811)| | Audit (CP 7348.810)| | Audit (CP 7348.808)|
+-------------------+ +-------------------+ +-------------------+
| | |
+-----------------------+-----------------------+
|
v
+-------------------------------------------------------------------------+
| BIMO Inspection Reports Submitted to CDRH |
+-------------------------------------------------------------------------+
|
+-------------------------+-------------------------+
| |
v v
+-------------------------------------+ +-------------------------------------+
| All Sites NAI / VAI: | | Any Key Site OAI / Data Compromised|
| BiMo Sign-Off Approved for PMA | | PMA Approval WITHHELD; Approvable |
| Decision | | Letter Conditioned on Remediation |
+-------------------------------------+ +-------------------------------------+
Key Rule: CDRH will not issue a final PMA approval order until the Division of Bioresearch Monitoring completes its review of all assigned BIMO inspection reports and formally signs off that the supporting clinical and nonclinical data are reliable.
The Pending Modernization of 21 CFR Part 58 GLP
The text of 21 CFR Part 58 was codified in 1978 and amended in 1987. Over the subsequent four decades, biomedical research evolved dramatically—moving from single-site domestic laboratories to complex, multi-country nonclinical studies relying on electronic records and advanced analytical instrumentation.
Rulemaking History and Status
FDA recognized that Part 58 needed structural modernization to reflect modern quality management systems:
- 2006: FDA launched the internal BIMO Modernization Initiative.
- December 2010: FDA published an Advance Notice of Proposed Rulemaking (ANPRM, 75 FR 80011 / FR 2010-31888) seeking public comment on revising Part 58.
- August 24, 2016: FDA published a comprehensive Notice of Proposed Rulemaking (NPRM, 81 FR 58542 / FR 2016-19875), titled Good Laboratory Practice for Nonclinical Laboratory Studies.
- Current Status (2026): The 2016 proposed rule remains un-finalized. While the rule has not yet achieved final codification, FDA field inspectors increasingly utilize the principles articulated in the proposed rule during GLP laboratory inspections.
Key Changes Introduced in the GLP Modernization Proposal
If finalized, the modernized Part 58 will introduce fundamental shifts for medical device safety testing:
+-----------------------------------------------------------------------------------+
| KEY STRUCTURAL CHANGES IN PENDING GLP MODERNIZATION |
+-----------------------------------------------------------------------------------+
| 1. GLP Quality System |
| Establishes an overarching GLP Quality System requirement, aligning GLP with |
| ISO 17025 and ISO 13485 QMS principles. |
| |
| 2. Expanded Scope Across All FDA Product Area Submissions |
| Explicitly covers all nonclinical safety studies supporting regulatory |
| submissions across devices, drugs, biologics, and tobacco products. |
| |
| 3. Formal Recognition of Multisite Studies |
| Defines specific regulatory roles for "Contributing Scientists" and "Test |
| Sites" when biocompatibility testing is split across multiple global labs. |
| |
| 4. Modernized Electronic Records and Equipment Controls |
| Harmonizes Part 58 with 21 CFR Part 11 for electronic data capture, computer |
| system validation (CSV), and automated laboratory instrumentation. |
+-----------------------------------------------------------------------------------+
Foreign CRO Data Integrity: 2025 Enforcement Lessons
In recent years, cost considerations have driven many device sponsors to contract nonclinical biocompatibility and animal safety studies to overseas Contract Research Organizations, particularly in Asia. However, FDA's Office of Bioresearch Monitoring Inspectorate maintains a dedicated foreign inspection cadre that actively inspects overseas GLP laboratories supporting U.S. device submissions.
Case Study: FDA Warning Letter to Jiangsu Kerbio (July 11, 2025)
A striking example of foreign BIMO enforcement occurred on July 11, 2025, when FDA issued a formal Warning Letter to Jiangsu Kerbio Medical Technology Group Co. (MARCS-CMS 705188), a Chinese contract testing laboratory that conducted biocompatibility and nonclinical safety studies for medical device manufacturers.
During an on-site BIMO inspection under CP 7348.808, FDA investigators uncovered widespread data integrity failures across 67 nonclinical studies:
- Fabricated and Retroactive Records: Investigators discovered study records, raw data worksheets, and animal observation logs that had been filled out retroactively. In multiple instances, observation sheets were signed for dates when technicians were not present at the facility.
- Dual SOP Systems: The facility maintained two conflicting sets of Standard Operating Procedures—a simplified domestic SOP set used during routine testing and a secondary "GLP SOP" set presented only during FDA inspections.
- QAU Breakdown: The Quality Assurance Unit failed to perform independent phase inspections and signed off on final reports containing clear data discrepancies.
Impact on Device Sponsors
When FDA issues an OAI warning letter to a foreign GLP CRO:
- Data Rejection: FDA rejects biocompatibility and safety data generated by that facility across all pending 510(k) and PMA submissions.
- Re-Testing Mandates: Affected device sponsors must re-conduct all biocompatibility testing at an accredited, GLP-compliant laboratory, delaying product launches by 6 to 18 months and incurring hundreds of thousands of dollars in unbudgeted testing costs.
- Import Alerts: FDA may place the foreign testing facility on Import Alert or issue public notifications warning device sponsors against using unverified offshore testing vendors.
BIMO and GLP Compliance Checklist for Device Sponsors
To ensure inspection readiness and safeguard regulatory submissions, medical device sponsors should implement a rigorous BIMO/GLP oversight protocol:
1. Nonclinical GLP Vendor Oversight
- On-Site Vendor Qualification: Perform a formal GLP audit of any contract laboratory before placing biocompatibility or animal safety studies. Do not rely solely on ISO 17025 accreditation certificates.
- Verify QAU Independence: Confirm that the testing facility's QAU reports to facility management and operates independently of Study Directors and testing personnel.
- Protocol and Raw Data Auditing: Audit study protocols prior to study initiation. Inspect original raw data worksheets and electronic data files to verify contemporaneous data entry.
- Multisite Study Traceability: If a biocompatibility study splits testing (e.g., chemistry at one lab, animal implantation at another), ensure clear Study Director control and contributing scientist SOP alignment.
2. Clinical Trial Site and CRO Oversight (IDE Studies)
- Robust Sponsor Monitoring Plan: Establish a risk-based clinical monitoring plan under 21 CFR Part 812. Ensure frequent on-site or remote source data verification (SDV).
- Unanticipated Adverse Device Effect (UADE) Protocols: Enforce strict 10-day reporting workflows for UADEs to FDA, IRBs, and participating investigators.
- Investigator Regulatory Files: Maintain complete regulatory binders for every clinical investigator, including signed Form FDA 1572 / investigator agreements, CVs, financial disclosures (21 CFR Part 54), and IRB approval letters.
- Investigator Disqualification Screen: Screen all potential clinical investigators against the FDA Clinical Investigators Disqualification Proceedings Database prior to site selection.
Frequently Asked Questions (FAQ)
Does BIMO apply to device 510(k) submissions or only to PMA clinical trials?
BIMO applies to all FDA regulatory submissions, including 510(k) premarket notifications, De Novo requests, IDE applications, and PMAs. While 510(k)s rarely require human clinical trials, they almost always contain nonclinical safety and biocompatibility testing governed by 21 CFR Part 58 GLP. FDA audits these nonclinical studies under BIMO Compliance Program 7348.808.
What is the difference between GLP (21 CFR Part 58) and GCP, and which applies to my biocompatibility lab?
GLP (21 CFR Part 58) governs nonclinical laboratory safety and biocompatibility studies (in vitro and in vivo animal testing). GCP (21 CFR Parts 50, 56, and 812) governs human clinical investigations. Biocompatibility testing facilities must comply strictly with GLP (Part 58), not GCP.
If a BIMO inspection classifies my investigator OAI, can I still use that site's data in my submission?
Generally, no. An OAI classification indicates severe noncompliance or data integrity failure. FDA routinely excludes data from OAI sites. To salvage the submission, the sponsor must demonstrate through an independent third-party audit that specific data points remain valid, or perform sensitivity analyses showing that overall study conclusions hold even when the OAI site's data is completely removed.
Has the FDA finalized the 2016 proposal to modernize 21 CFR Part 58?
No. As of August 2026, the 2016 proposed rule (81 FR 58542) remains un-finalized. However, FDA inspectors frequently utilize the proposed rule's principles—particularly regarding GLP Quality Systems, multisite study management, and computer system validation—as benchmark expectations during BIMO laboratory audits.
Related Guides and Resources
For further analysis of medical device clinical evidence, quality systems, and regulatory testing, explore our related guides:
- ISO 10993 Biocompatibility Testing Guide — Comprehensive evaluation of biological endpoints, test selection, and chemical characterization.
- Good Clinical Practice (GCP) for Device Trials — Ethical and regulatory requirements for conducting human clinical investigations.
- Medical Device CRO Selection Guide — How to evaluate, contract, and audit contract research organizations for clinical and nonclinical studies.
- IDE Clinical Investigations Guide — Regulatory approval and trial execution under 21 CFR Part 812.
- FDA 522 Postmarket Surveillance Studies — Requirements and BIMO oversight for postmarket surveillance orders.